The thesis

Bausch Health Companies operates in the healthcare sector with a diverse portfolio of products. The company has a revenue growth of 12.7% year-over-year, but its net margin is -1012.0%. The conviction score is 37 out of 100, indicating a watchlist status. The analyst consensus rating is buy, despite the company's negative net margin and low conviction score.

Why now

The current macro context, including China's chip tool push and the US-China squeeze, may impact BHC's operations. The company's low conviction score and negative net margin make it a compelling watchlist candidate, especially with a revenue growth of 12.7% year-over-year.

What to watch

The company's future revenue growth and net margin will be key indicators to watch over the next quarter. A significant improvement in net margin, combined with continued revenue growth, would confirm the thesis and potentially increase the conviction score.

Key risks

The company's negative net margin of -1012.0% poses a significant valuation risk. Execution risk is also a concern, given the company's diverse portfolio of products. Additionally, macro risks such as the US-China trade tensions may impact BHC's operations.

Upcoming catalysts